
Naiyu Zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4847794/publications.pdf Version: 2024-02-01



NAIVU ZHENC

#	Article	IF	CITATIONS
1	High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma. Analytical Chemistry, 2021, 93, 834-842.	6.5	12
2	Automated and high-throughput extraction approaches. , 2020, , 573-588.		4
3	Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues. Analytical Chemistry, 2020, 92, 14713-14722.	6.5	15
4	Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMSâ€986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo ontrolled trial in healthy participants. British Journal of Clinical Pharmacology, 2020, 86, 1849-1859.	2.4	17
5	Accelerating protein biomarker discovery and translation from proteomics research for clinical utility. Bioanalysis, 2020, 12, 1469-1481.	1.5	10
6	Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC–MS. Bioanalysis, 2019, 11, 785-795.	1.5	13
7	Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy. Pharmaceutical Research, 2019, 36, 164.	3.5	11
8	Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis. Analytical Chemistry, 2019, 91, 8652-8659.	6.5	17
9	Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS. Analytical Chemistry, 2019, 91, 8443-8452.	6.5	10
10	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). Journal of Medicinal Chemistry, 2019, 62, 3228-3250.	6.4	78
11	A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 165, 198-206.	2.8	9
12	In-Sample Calibration Curve Using Multiple Isotopologue Reaction Monitoring of a Stable Isotopically Labeled Analyte for Instant LC-MS/MS Bioanalysis and Quantitative Proteomics. Analytical Chemistry, 2019, 91, 2536-2543.	6.5	20
13	Synthesis of an adenine N-3 substituted CBI adduct by alkylation of adenine with a 1-iodomethylindoline seco-CBI precursor. Tetrahedron, 2018, 74, 6680-6688.	1.9	Ο
14	LC–MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drug–drug interactions. Bioanalysis, 2018, 10, 1473-1485.	1.5	5
15	Critical considerations for immunocapture enrichment LC–MS bioanalysis of protein therapeutics and biomarkers. Bioanalysis, 2018, 10, 987-995.	1.5	10
16	Drug Metabolism: Metabolite Isolation and Identification. , 2018, , 232-232.		1
17	Differential mobility spectrometry combined with multiple ion monitoring for bioanalysis of disulfide-bonded peptides with inefficient collision-induced dissociation fragmentation. Bioanalysis, 2017, 9, 183-192.	1.5	11
18	UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug–drug interactions. Bioanalysis, 2016, 8, 2429-2443.	1.5	3

NAIYU ZHENG

#	Article	IF	CITATIONS
19	Quantitation of a PEGylated protein in monkey serum by UHPLC-HRMS using a surrogate disulfide-containing peptide: A new approach to bioanalysis and inÂvivo stability evaluation of disulfide-rich protein therapeutics. Analytica Chimica Acta, 2016, 916, 42-51.	5.4	11
20	Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection. Analytica Chimica Acta, 2016, 934, 170-179.	5.4	22
21	The Â-Secretase Modulator, BMS-932481, Modulates AÂ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 138-150.	2.5	37
22	A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 119, 145-151.	2.8	6
23	"Center punch―and "whole spot―bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 988, 66-74.	2.3	38
24	Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography – tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range. Journal of Chromatography A, 2015, 1424, 27-36.	3.7	35
25	Current advances and strategies towards fully automated sample preparation for regulated LC–MS/MS bioanalysis. Bioanalysis, 2014, 6, 2441-2459.	1.5	36
26	A validated LC–MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 973, 1-8.	2.3	19
27	Improved liquid–liquid extraction with inter-well volume replacement dilution workflow and its application to quantify BMS-927711 in rat dried blood spots by UHPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2014, 89, 240-250.	2.8	9
28	A rapid, accurate and robust UHPLC–MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2013, 83, 237-248.	2.8	12
29	A simplified and completely automated workflow for regulated LC–MS/MS bioanalysis using cap-piercing direct sampling and evaporation-free solid phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 921-922, 64-74.	2.3	6
30	A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis. Journal of the Association for Laboratory Automation, 2012, 17, 211-221.	2.8	20
31	Esterase inhibitors as esterâ€containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2012, 26, 1291-1304.	1.5	11
32	A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. Analytical Chemistry, 2011, 83, 6237-6244.	6.5	23
33	Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC–MS/MS. Bioanalysis, 2010, 2, 733-743.	1.5	43
34	Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry—Evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 77-84.	2.3	28
35	Utility of porous graphitic carbon stationary phase in quantitative liquid chromatography/tandem mass spectrometry bioanalysis: quantitation of diastereomers in plasma. Rapid Communications in Mass Spectrometry, 2006, 20, 1831-1837.	1.5	24
36	Synthesis of the stable isotope labeled antiviral nucleoside analog [8-13C–7,9-15N2]-ganciclovir. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1131-1139.	1.0	0

Naiyu Zheng

#	Article	IF	CITATIONS
37	Characterization of an Etoposide-Glutathione Conjugate Derived from Metabolic Activation by Human Cytochrome P450. Current Drug Metabolism, 2006, 7, 897-911.	1.2	14
38	Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide. Clinical Cancer Research, 2004, 10, 2977-2985.	7.0	22
39	Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. Journal of Mass Spectrometry, 2001, 36, 771-781.	1.6	36
40	The isolation and structure of bacillariolide III, an extracellular metabolite of the diatom, Pseudo-nitzschia multiseries. Chemical Communications, 1997, , 399-400.	4.1	18